Brief: Candel Therapeutics - Expects Topline Data From Phase 2 Clinical Trial Of CAN-2409 In Q2 Of 2024
13/06/2023 14:15
June 13 (Reuters) - Candel Therapeutics Inc CADL.O :
* CANDEL THERAPEUTICS ANNOUNCES IT EXPECTS TO REPORT TOPLINE
DATA
FROM ITS PHASE 2 CLINICAL TRIAL OF CAN-2409 IN NON-SMALL CELL
LUNG CANCER IN THE SECOND QUARTER OF 2024
Source text for Eikon: ID:nGNX2by7xY
Further company coverage: CADL.O
(reuters.briefs@thomsonreuters.com)
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec